Corbus Pharmaceuticals Holdings (STU:3371) NonCurrent Deferred Liabilities : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Corbus Pharmaceuticals Holdings NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Corbus Pharmaceuticals Holdings's non-current deferred liabilities for the quarter that ended in Mar. 2025 was €0.00 Mil.

Corbus Pharmaceuticals Holdings NonCurrent Deferred Liabilities Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings NonCurrent Deferred Liabilities Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Corbus Pharmaceuticals Holdings NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (STU:3371) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

CRBP:USA 0SZI:UK

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Headlines

No Headlines